.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Harvard Business School
Chubb
Teva
US Department of Justice
Mallinckrodt
Dow
Citi
Novartis
Chinese Patent Office

Generated: September 26, 2017

DrugPatentWatch Database Preview

ALPHAGAN Drug Profile

« Back to Dashboard

What is the patent landscape for Alphagan, and when can generic versions of Alphagan launch?

Alphagan is a drug marketed by Allergan and is included in four NDAs. There are seven patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in ALPHAGAN is brimonidine tartrate. There are eleven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.

Summary for Tradename: ALPHAGAN

Patents:0
Applicants:1
NDAs:4
Suppliers / Packagers: see list1
Bulk Api Vendors: see list47
Clinical Trials: see list16
Patent Applications: see list865
Drug Prices:see details
DailyMed Link:ALPHAGAN at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
ALPHAGAN
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC020613-001Sep 6, 1996DISCNYesNo► Subscribe► Subscribe► Subscribe
Allergan
ALPHAGAN P
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC021262-001Mar 16, 2001ATRXYesYes► Subscribe► SubscribeY► Subscribe
Allergan
ALPHAGAN P
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC021262-001Mar 16, 2001ATRXYesYes► Subscribe► SubscribeY► Subscribe
Allergan
ALPHAGAN P
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC021770-001Aug 19, 2005RXYesYes► Subscribe► SubscribeY► Subscribe
Allergan
ALPHAGAN P
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC021770-001Aug 19, 2005RXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan
ALPHAGAN P
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC021770-001Aug 19, 2005RXYesYes► Subscribe► SubscribeY► Subscribe
Allergan
ALPHAGAN
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC020490-001Mar 13, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe
Allergan
ALPHAGAN P
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC021262-001Mar 16, 2001ATRXYesYes► Subscribe► SubscribeY► Subscribe
Allergan
ALPHAGAN P
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC021262-001Mar 16, 2001ATRXYesYes► Subscribe► SubscribeY► Subscribe
Allergan
ALPHAGAN P
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC021262-001Mar 16, 2001ATRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ALPHAGAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan
ALPHAGAN
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC020613-001Sep 6, 1996► Subscribe► Subscribe
Allergan
ALPHAGAN
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC020613-001Sep 6, 1996► Subscribe► Subscribe
Allergan
ALPHAGAN
brimonidine tartrate
SOLUTION/DROPS;OPHTHALMIC020613-001Sep 6, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for ALPHAGAN

Drugname Dosage Strength RLD Submissiondate
brimonidine tartrateOphthalmic Solution0.10%Alphagan P12/20/2006
brimonidine tartrateOphthalmic Solution0.15%Alphagan P11/3/2006
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Daiichi Sankyo
Deloitte
US Department of Justice
Baxter
McKesson
Healthtrust
Cipla
US Army
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot